glp 1 agonist muscle loss Weight with GLP-1 medicines does not result in a disproportionate loss of mass or function in obese mice and humans: Cell Reports Medicine Muscle Loss with GLP-1 Medications:

Diabetes mellitus increases risk of incident dementia in APOEvarepsilon4 carriers: A meta-analysis

CDSCO has approved semaglutide for prescription by endocrinologists and internal medicine specialists for diabetes and obesity indications

Beyond their role in glucose metabolism, GLP-1 and its receptor agonists have emerged as multifunctional agents with broad cardiometabolic, renal, and immunomodulatory benefits

Optum Rx has also introduced a host of changes to ensure GLP-1 drugs are used responsibly, including optional utilization management (UM) and enhanced system edits

& Schwartz, T

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update